These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The prognostic significance of progesterone receptor level in endometrial cancer]. Nyholm HC; Christensen IJ; Nielsen AL Ugeskr Laeger; 1997 Jan; 159(5):601-4. PubMed ID: 9045451 [TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596 [TBL] [Abstract][Full Text] [Related]
5. [Measurement of estrogen receptor and progesterone receptor in human endometrium and endometrial carcinoma]. Itoh E Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):812-20. PubMed ID: 2196312 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591 [TBL] [Abstract][Full Text] [Related]
8. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma. Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107 [TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247 [TBL] [Abstract][Full Text] [Related]
11. [Estrogen and progesterone receptors in endometrial carcinoma]. Guo Y; Dang Q Zhonghua Fu Chan Ke Za Zhi; 1997 Jul; 32(7):418-21. PubMed ID: 9639729 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. Suthipintawong C; Wejaranayang C; Vipupinyo C J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083 [TBL] [Abstract][Full Text] [Related]
15. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
16. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions]. Ma XX; Zhang SL; Gao S; Lu JM; Dong F Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363 [TBL] [Abstract][Full Text] [Related]
17. Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis. Nyholm HC; Nielsen AL; Lyndrup J; Dreisler A; Thorpe SM Int J Gynecol Pathol; 1993 Jul; 12(3):246-52. PubMed ID: 7688353 [TBL] [Abstract][Full Text] [Related]
18. [Cytosol estrogen and progesterone receptors in female genital system malignant tumors]. Han SW; He B; Tang QP Zhonghua Fu Chan Ke Za Zhi; 1994 Jan; 29(1):12-5, 59. PubMed ID: 8033616 [TBL] [Abstract][Full Text] [Related]
19. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124 [TBL] [Abstract][Full Text] [Related]